Action EXPRS2 EXPRES2ION BIOTECH HOLDING AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués ExpreS2ion Biotech Holding AB

Actions

EXPRS2

SE0008348262

Marché Fermé - Nasdaq Stockholm
Autres places de cotation
 18:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
1,16 SEK -0,17% Graphique intraday de ExpreS2ion Biotech Holding AB +7,41% -45,02%
16/05 ExpreS2ion Biotech Holding AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
16/04 ExpreS2ion annonce l'achèvement de l'étude de sécurité GLP pour le candidat vaccin ES2B-C001 (HER2-VLP) contre le cancer du sein CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Rights issue subscription period ending 27 June 2024; subscription possible via form
AQ
ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting
AQ
Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
AQ
ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine
AQ
BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I
AQ
ExpreS2ion CEO to BioStock: "Compelling preclinical package gives us confidence"
AQ
The subscription period in ExpreS2ion's rights issue begins today
AQ
ExpreS2ion to present in upcoming investor and scientific events
AQ
ExpreS2ion publishes prospectus in connection with its rights issue of units
AQ
Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024
AQ
ExpreS2ion Biotech : Interim report for January – March 2024 (Q1)
PU
ExpreS2ion announces financial results for the first quarter of 2024
AQ
ExpreS2ion to present in spring investor events
AQ
ExpreS2ion Biotech : Annual report 2023 including Auditor’s report
PU
ExpreS2ion annual report for 2023 published
AQ
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)
AQ
ExpreS2ion announces a rights issue of units of approximately SEK 60 million
AQ
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS
AQ
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023
AQ
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action EXPRS2
  4. Actualités ExpreS2ion Biotech Holding AB
  5. Communiqués